Supplement can reverse diabetic damage
In the wake of the Avandia scandal, I’ve been searching the planet for a better, safer and more effective way to reverse the damage caused by diabetes.
And you’re not going to believe where I found it: Right in Big Pharma’s backyard!
It’s called benfotiamine — and while it’s sold as a prescription “drug” overseas, it’s really just a synthetic derivative of ordinary vitamin B1, a.k.a., thiamine.
There’s just one big difference between the two: While thiamine is water soluble, benfotiamine is fat soluble — and that allows your body to absorb it five times more efficiently.
The result: a diabetes repair kit that puts the other Big Pharma drugs to shame.
Benfotiamine takes excess blood sugar and puts it to work — restoring balance by allowing your blood cells to use the glucose instead of becoming overrun with the stuff.
But that’s not even close to all it does.
It can actually reverse the damage caused by high blood sugar, including kidney and nerve damage.
It’s like getting your life back.
Now, if Big Pharma would just start selling this stuff here in the United States, I’d give the devil his due — and say this is a rare case of a drug that works (even if it is just a synthetic vitamin).
But they wouldn’t dare — because the U.S. happens to be the world’s most lucrative diabetes market, and benfotiamine is so safe, effective and inexpensive that it would wipe out that multibillion-dollar industry overnight.
Now, I can practically hear what you’re thinking at this point: If it’s that good, why haven’t I heard of it?
Trust me — it is that good. And while you may not have heard of it, researchers have. It’s been studied for decades now — and the science behind it is rock solid.
In fact, if this was a movie, I could make a poster filled with glowing blurbs — like this one from the journal Diabetes/Metabolism Research and Reviews: “an inexpensive approach to the prevention and/or treatment of diabetic complications.”
Or maybe this one, from Pharmacological Research: “effective for the treatment of diabetic neuropathy, nephropathy and retinopathy.”
Circulation: Heart Failure: “protects from diabetes mellitus-induced cardiac dysfunction” and “merits attention
for application in clinical practice.”
Even in other languages, the results are the same — this was in Serbian Archives for the Whole Medicine last year: “significant subjective and objective improvement” and “a good starting choice” for diabetic polyneuropathy.
I didn’t cherry-pick these, by the way. You can look it up yourself if you want — and you’ll find that the glowing research isn’t limited to diabetes. Other studies have found that benfotiamine may help treat or lower the risk of everything from Alzheimer’s disease to heart problems.
The only problem is getting it. It’s hard to find, and there’s no way to be sure of what you’re getting when you do find it.
At some point, U.S. consumers will start to demand benfotiamine — especially when word gets out over how effective it is overseas — and you’ll see every diabetic taking it.
My prediction: It’ll be game over for Big Pharma’s diabetes drugs when that does happen.
The only question is, will it be too late for you?